

Revance Therapeutics (RVNC : US\$31.77)

Revance Therapeutics climbs 18% in 2014, outperforming 82% of the market

Revance Therapeutics Inc, has now climbed US\$4.84 (or 18%) year to date in 2014 to close at US\$31.77. This gain means the stock has outperformed 82% of NASDAQ-listed stocks in 2014. The volume YTD has been 0.6 times average trading of 192,662 shares. Compared with the NASDAQ-100 Index which has risen 6.7% YTD, this represents a relative price increase of 11.3%. In 2014 the market cap has jumped US\$114.7 million.

Introduction

We are currently bearish on this stock, both in the short-term based on technical indicators, as well as in the long-term based on fundamental metrics

What makes us most bearish on the stock is the following:

- Its Moving Average Convergence Divergence indicators are falling, with its 12-day EMA lower than its 26-day EMA.
- The stock is overbought according to the Williams % R indicator of -9.9.
- In the last three months the number of falls outnumbered rises 40:20 or 2.0:1.

Stock Summary

Sector	Total NASDAQ Market
Market Cap	US\$592.6 million
Shares Outstanding	18,651,754
ISIN	US7613301099
Relative Strength (3 mo)	22

MCap: A Historical Perspective

	Share Price (USD)	Market Cap (\$)
Last	31.8	592.6 million

Analysis

Bullish Signals

- In the last 8 trading sessions there has been a net rise of 1.15%; the stock has advanced nine times and the biggest one day rise was 7.2% on Jun 10.

Other Bullish Signals:

Note

Neutral Indicators and Rank in Market:

Description	Value	Rank In Market
Turnover in Quarter	US\$367.9 million	In 2nd Quartile
MCap	US\$592.6 million	In 2nd Quartile

Bearish Signals:


- The price is at a premium of 1.7% to the 1-month volume weighted average price (VWP) of US\$31.23. Given that this premium has been under 1.7% fifty-three times and over 1.7% twenty-six times in the last year, the downside:upside probability is estimated at 53:26 or 2.04:1.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 30.59 minus the 26-day EMA of 30.97 is negative suggesting a bearish signal.
- The stock is overbought according to the Williams % R indicator of -9.9.
- The current short volume is 2.3 times its own historical average of 0.2%.

Other Bearish Signals:

Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Volatility %	4.6	In Bottom Quartile
Price/MAP50	0.61	In Bottom 7%

Turnover Rate & Turnover Period




Trailing 3 months

Turnover	US\$367.9 million
Volume	11,525,635
Volume Index (1 is avg)	0.9


Price Volume Trend: Trailing Quarter



Weekly Price Volume Dynamics (Last 12 Weeks)



Stock v Index (Trailing Year)



Company Overview

Activities

Revance Therapeutics, Inc. produces biopharmaceutical products. The Company develops drug delivery and treatments for dermatology and aesthetic medicine. Revance Therapeutics serves patients and doctors throughout the United States.

Further details can be found at
www.revance.com.

Regulatory Announcements

To view Recent Company Headlines, [click here](#)

June 16: Revance Therapeutics Announces Proposed Public Offering of Common Stock
May 21: Revance Therapeutics, Inc. Announces Participation in Jefferies 2014 Global Healthcare Conference
May 13: Revance Therapeutics Releases First Quarter 2014 Financial Results
May 12: Revance Therapeutics appoints Director
April 29: Revance Therapeutics to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014
April 21: Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines
March 31: Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes

To view 8-K other news for Revance-Therapeutics, [click here](#)

March 26: Revance Therapeutics: Results of Operations and Financial Condition
March 04: Revance Therapeutics: Entry into a Material Definitive Agreement
February 11: Revance Therapeutics: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year


Issued Capital

Based on 18,651,754 issued equity shares the market capitalisation is US\$592.6 million.
The top sixteen shareholders hold 40.7% of the issued capital leaving a float of 59.3%.

Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Essex Woodlands Health Ventures Inc.	4,592,047	24.62
Waddell & Reed Financial Inc	529,757	2.84
Millennium Management Llc	321,082	1.72
Rs Investment Management Co Llc	316,000	1.69
Camber Capital Management Llc	300,000	1.61
Jpmorgan Chase & Co	269,200	1.44
Polar Capital Llp	247,453	1.33
Blackrock Fund Advisors	189,747	1.02
Jennison Associates Llc	174,972	0.94
Barclays Global Investors Uk Holdings Ltd	151,593	0.81
Total	7,091,851	38.02

Top 16 Institutional Holdings



Board and Management

Angus C. Russell Chairman

Creation of shareholder value in Revance Therapeutics:

Since appointment as Chairman: The present value of USD1,000 invested on the appointment date of March 05, 2014 at close price of US\$31.61 is US\$1,005, for a capital gain of US\$5.

Mark A. Prygocki Director

Mr. Prygocki is a pharmaceutical industry leader with over 20 years of experience, specializing in corporate finance, commercial operations, and manufacturing and distribution. He was employed by Medicis Pharmaceutical Corporation for more than 20 years and served as President from July 2010 to December 2012. Prior to July 2010, Mark Prygocki held several senior-level positions at Medicis, including Chief Operating Officer, Executive Vice President, and Chief Financial Officer and Treasurer. From July 1990 through October 1991, he was employed by Citigroup, an investment banking firm, in the regulatory reporting division. Prior to that, Mr. Prygocki spent several years in the audit department of Ernst & Young, LLP. He is certified by the Arizona State Board of Accountancy and the New York Society of CPAs. During his tenure at Medicis, Mark played a pivotal role in the launch and commercial success of a vast portfolio of dermatological products, including RESTYLANE(Registered), PERLANE(Registered), DYSPORT(Registered), SOLODYN(Registered), ZIANA(Registered), VANOS(Registered), and LOPROX(Registered). Under his leadership, Medicis grew to become a multi-billion dollar enterprise and was acquired by Valeant Pharmaceuticals International in 2012 for \$2.6 billion.

Creation of shareholder value in Revance Therapeutics:

Since appointment as Director: The present value of USD1,000 invested on the appointment date of May 12, 2014 at close price of US\$31.21 is US\$1,018, for a capital gain of US\$18.

Financial Results (Quarterly)

31 March, 2014

INCOME STATEMENT

Currency in Thousand of USD	2014-03-31	2013-03-31	Change %
Revenue	158	75	Up 110.7
Cost of revenue			
Gross profit	158	75	Up 110.7
Operating expenses:			
Research and development	7,551	7,527	Up 0.3
Sales, general and administrative	4,093	2,225	Up 84.0
Total operating expenses	11,644	9,752	Up 19.4
Loss from operations	-11,486	-9,677	Deterioration 18.7
Interest income	2		
Interest expense	9,841	12,624	Down 22.0
Change in fair value of derivative liabilities associated with convertible notes	4,032	1,800	Up 124.0
Changes in fair value of derivative liabilities associated with Medicis settlement	-416		
Change in fair value of common stock warrant liability	-2,151		
Change in fair value of convertible preferred stock warrant liability	-210	-1,158	Reduced 81.9
Loss on settlement of preferred stock warrant	-1,356		
Other income, net		2	
Loss before income taxes	-21,426	-21,657	Reduced 1.1
Benefit from income taxes			
Net and comprehensive loss	-21,426	-21,657	Reduced 1.1
Net income (loss) attributable to common stockholders:			
Basic	-21,426	5,216	Deterioration
Diluted	-21,426	13,349	Deterioration
Net income (loss) per share attributable to common stockholders:			
Basic	-193.0c	US\$25.54	Deterioration
Diluted	-193.0c	US\$21.0	Deterioration
Weighted-average number of shares used in computing net income (loss) per share attributable to common stockholders:			
Basic	11,092,471	204,220	Up 5,331.6
Diluted	11,092,471	635,726	Up 1,644.9

BALANCE SHEET

Currency in Thousand of USD	2014-03-31	2013-12-31	Change %
ASSETS			

Financial Results (Quarterly) (continued)

31 March, 2014

CURRENT ASSETS			
Cash and cash equivalents	87,853	3,914	Up 2,144.6
Restricted cash, current portion	75	75	Steady
Prepaid expenses and other current assets	3,244	825	Up 293.2
Total current assets	91,172	4,814	Up 1,793.9
Property and equipment, net	15,150	14,315	Up 5.8
Restricted cash, net of current portion	435	510	Down 14.7
Other non-current assets	155	3,006	Down 94.8
TOTAL ASSETS	106,912	22,645	Up 372.1
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)			
CURRENT LIABILITIES			
Accounts payable	3,689	5,526	Down 33.2
Accruals and other current liabilities	5,515	4,161	Up 32.5
Deferred revenue, current portion		83	
Derivative liabilities associated with convertible notes, current portion		4,890	
Derivative liabilities associated with Medicis settlement, current portion		6,684	
Convertible notes, current portion		12,157	
Notes payable, current portion	13,405	10,702	Up 25.3
Common stock warrant liability		3,358	
Total current liabilities	22,609	47,561	Down 52.5
Convertible preferred stock warrant liability		1,233	
Note payable, net of current portion and discount	400	2,632	Down 84.8
Derivative liabilities associated with Medicis settlement, net of current portion	1,637	1,610	Up 1.7
Deferred rent	3,579	3,176	Up 12.7
TOTAL LIABILITIES	28,225	56,212	Down 49.8
Commitments and Contingencies			
Convertible preferred stock, par value 0.001 per share 5,000,000 shares and 145,010,269 shares authorized as of March 31, 2014 and December 31, 2013, respectively; 0 shares and 8,689,999 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively (aggregate liquidation preference of 0 and 215,264 as of March 31, 2014 and December 31, 2013, respectively)		123,982	
STOCKHOLDERS' EQUITY (DEFICIT)			
Common stock, par value 0.001 per share 95,000,000 and 19,224,000,000 shares authorized as of March 31, 2014 and December 31, 2013, respectively; 18,653,301 and 260,789 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively			
Additional paid-in capital	295,974	38,331	Up 672.2
Deficit accumulated during the development stage	-217,306	-195,880	Deterioration 10.9
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	78,667	-157,549	Recovery
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)	106,912	22,645	Up 372.1

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews "hot tip" or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.
